BDSI - BioDelivery Sciences International, Inc.
| Previous Close | 3.64 |
| Open | 3.62 |
| Bid | 3.20 x 900 |
| Ask | 5.32 x 1200 |
| Day's Range | 3.50 - 3.70 |
| 52 Week Range | 1.70 - 3.90 |
| Volume | 321,797 |
| Avg. Volume | 498,507 |
| Market Cap | 209.053M |
| Beta (3Y Monthly) | -0.17 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings Date | Nov 7, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.80 |
- GlobeNewswire•6 days ago
New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•11 days ago
Can The Uptrend Continue for BioDelivery Sciences International (BDSI)?
Investors certainly have to be happy with BioDelivery Sciences International, Inc. (BDSI) and its short term performance.
- American City Business Journals•18 days ago
From Iqvia's Bousbib to Red Hat's Whitehurst: Who made the most from inside stock sales in 3Q2018
From Iqvia to Red Hat to Bandwidth, insiders at Triangle companies continued to rake in millions in the third quarter by selling shares, U.S. Securities and Exchange Commission filings show.
- Simply Wall St.•22 days ago
Who Are The Major Shareholders Of BioDelivery Sciences International Inc (NASDAQ:BDSI)?
The big shareholder groups in BioDelivery Sciences International Inc (NASDAQ:BDSI) have power over the company. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
- GlobeNewswire•28 days ago
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
RALEIGH, N.C., Sept. 25, 2018-- BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced ...
- GlobeNewswire•last month
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
RALEIGH, N.C., Sept. 13, 2018-- BioDelivery Sciences International, Inc., a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced ...
- GlobeNewswire•last month
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
RALEIGH, N.C., Sept. 10, 2018-- BioDelivery Sciences International, Inc., a leading commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that ...
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of BDSI earnings conference call or presentation 9-Aug-18 8:30pm GMT
Q2 2018 BioDelivery Sciences International Inc Earnings Call
- GlobeNewswire•2 months ago
Factors of Influence in 2018, Key Indicators and Opportunity within Aurora Cannabis, Canopy Growth, MobileIron, Sangamo Therapeutics, BioDelivery Sciences International, and First Solar — New Research Emphasizes Economic Growth
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aurora ...
- GlobeNewswire•2 months ago
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
RALEIGH, N.C., Aug. 21, 2018-- BioDelivery Sciences International, Inc.,, a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm ...
- GlobeNewswire•2 months ago
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
RALEIGH, N.C., Aug. 15, 2018-- BioDelivery Sciences International, Inc., a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain today announced that a leading ...
- Zacks•2 months ago
BioDelivery (BDSI) Q2 Loss Narrows, Sales Miss, Shares Down
BioDelivery Sciences (BDSI) reports narrower-than-expected loss in Q2. Sales marginally miss the consensus mark.
- Zacks•2 months ago
BioDelivery Sciences International (BDSI) Reports Q2 Loss, Misses Revenue Estimates
BioDelivery (BDSI) delivered earnings and revenue surprises of 15.79% and -2.16%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
BioDelivery: 2Q Earnings Snapshot
The Raleigh, North Carolina-based company said it had a loss of 16 cents per share. The results topped Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
- GlobeNewswire•2 months ago
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
BELBUCA ® Continues Its Accelerated Record Prescription Growth of 80% YOY and 31% Versus the Prior Quarter. Company Provides Overview of New Plan to Capitalize on Long Term Net Revenue Potential of $200 ...
- ACCESSWIRE•2 months ago
BioDelivery Sciences International, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / BioDelivery Sciences International, Inc. (NASDAQ: BDSI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at ...
- Zacks•2 months ago
Drug/Biotech Stock Q2 Earnings on Aug 9: PRGO, BDSI & More
Several drug/biotech companies are set to report second-quarter results on Aug 9. Let's see how things are shaping up for their announcements.
- GlobeNewswire•3 months ago
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018. Paul Chaney, EyeGate’s Chairman, said, “We are pleased to welcome Peter Greenleaf to the EyeGate Board.
- Zacks•3 months ago
Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
- ACCESSWIRE•3 months ago
Free Stock Performance Review on Biogen and Three Additional Biotech Stocks
This morning, WallStEquities.com observes BioDelivery Sciences International Inc. (NASDAQ: BDSI), Biohaven Pharmaceutical Holding Co. Ltd (NYSE: BHVN), Biogen Inc. (NASDAQ: BIIB), and Cerus Corp. (NASDAQ: CERS). The Biotechnology industry consists of companies that are engaged in the research and development of new drugs, medical devices, and procedures. The industry includes the manufacturing and marketing of drugs as a result of direct research and development.
- GlobeNewswire•3 months ago
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
BioDelivery Sciences International, Inc. (BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with chronic pain has appointed Thomas B. Smith, MD, FAAFP, as Chief Medical Officer and member of the Company’s Executive Leadership Team. Dr. Smith brings nearly thirty years of medical experience and expertise in the field of pain management to BDSI. His extensive and wide-ranging roles include having been Chief Medical Officer at various leading pain companies, head of medical affairs at top tier pharma and CRO companies, as well as running his own private practice. Dr. Smith is a highly published scientific author and has delivered more than 150 presentations in his field of expertise.
